SLC5A2 and cardiovascular disorder: The recent introduction of sodium-glucose cotransporter-2 inhibitors into guidelines for heart failure in patients with and without T2DM has highlighted the importance of glucometabolic modulation in cardiovascular disease to improve patient outcomes [21].